If you go to the bottom of Behrenbruch's post and the reply you are referring to...
Look at the addendum dated 12/10/15. The comment about it being a pharmaceutical rather than a device is the issue (as all holders who have suffered through the last 2 years would know).
So you need to ask - what is the advantage of being a pharmaceutical classification over device classification. I can assure you it isnt just because the path to FDA approval is more difficult.
You need to be thinking more about the end game...
Behrenbruch is the leadership this company needed 3 years ago, so now we start.
TIS Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
